Pharmaguy's Insights Into Drug Industry News
194.4K views | +5 today
Pharmaguy's Insights Into Drug Industry News
Pharmaguy curates and provides insights into selected drug industry news and issues.
Curated by Pharma Guy
Your new post is loading...
Your new post is loading...
Scooped by Pharma Guy!

The Goose That Laid the Golden Egg: Based on Roche & Accutane

A psychiatrist risks all to expose a corrupt drug company.

Described as Erin Brockovich meets The Constant Gardener, THE GOOSE THAT LAID THE GOLDEN EGG is based on a true story that involves greed, power, lies, tragedy, danger, and death. It is also an inspirational and spiritual story, with themes of overcoming personal loss and personal redemption. The entirety of Psalm 46 is in the screenplay, which is written by Doug Bremner and Cathy Reinking.

Renzon Pharmaceuticals aren’t about to let a psychiatrist get in the way of their billion dollar a year miracle cure for acne. So when Dr. Johnny Forteo dares to question the potentially lethal side effect of their drug, Synoderm, they pull out the stops, ultimately leaving him jobless, friendless, wifeless – but not, completely hopeless.

Drawn into the medication controversy as an unwilling participant, he learns that he must confront the lies and deception in his own life before he can confront the lies and deceptions of others. With nothing left to lose, he goes on a journey to revisit a tragedy from his own past. Along the way he is joined by Ginny Bellaconda, the bereaved mother at the center of ongoing litigation with Renzon. When he unearths more painful secrets and deceptions that parallel those he has discovered in the pharmaceutical company, his voyage of self-discovery gives him strength to resume his struggle, now joined by Ginny, leading to the ultimate tumultuous conclusion.

From Amazon reader reviews of the well-reviewed non-fiction version of The Goose That Laid the Golden Egg:

“An indictment of the pharmaceutical industry... illuminates the greed and unscrupulous nature of pharmaceutical companies and their market driven interests.”

“A compelling and spell-binding narrative which fuses the personal and social in a heroic quest.”

“I was so fascinated (and horrified) once I started reading, I finished the book in a single day.”

No comment yet.
Scooped by Pharma Guy!

A Patient-Centric Petition Pleads with Roche for Lower Kadcyla Price

A Patient-Centric Petition Pleads with Roche for Lower Kadcyla Price | Pharmaguy's Insights Into Drug Industry News |

Drugmakers are accustomed to grappling with government payers and PBMs over prices. They're used to getting the stiff arm from cost-effectiveness watchdogs like those at the U.K.'s National Institute for Health and Care Excellence (NICE). They're even used to the critics at patient-access organizations.

But a pricing fight directly with patients? That's not your everyday occurrence.

A U.K. cancer survivor has gathered almost 30,000 signatures on a petition asking Roche to lower the price of its new breast cancer treatment Kadcyla. The breakthrough armed-antibody therapy is priced at about $94,000 for a 9-month course--or almost $150,000 when used as designed, alongside Roche's other new breast cancer drug, Perjeta.

The online petition's signatories are from all over the world, and some include comments alongside their signatures. A few are coolly rational--drug prices need to cover the cost plus a reasonable markup, one said--but others are emotional tirades. Not the sort of conversation drugmakers want to hear about themselves and their products online.

It's another sign that the fight over drug prices is spilling over from payers to the public, upturning the usual dynamic of cost-conscious payer on one side, and patients and drugmakers on the other.

Pharma Guy's insight:

This is a twist on the standard practice whereby drug companies hire patients to petition government to approval expensive cancer or orphan-disease drugs or medical procedures. Read, for example, Will 250,000 Morbidly Obese People Sign Allergan's Petition to Congress?

No comment yet.
Scooped by Pharma Guy!

Healthcare Businesswomen’s Association Names 2016 WOTY

Healthcare Businesswomen’s Association Names 2016 WOTY | Pharmaguy's Insights Into Drug Industry News |

The Healthcare Businesswomen’s Association (HBA) announced that its 2016 Woman of the Year is Jennifer Cook, head of pharma, region Europe for Roche. 

“The Healthcare Businesswomen’s Association is extremely proud to honor Jennifer Cook as our 2016 Woman of the Year,” says Laurie Cooke, CEO of the HBA. “Jennifer embodies the leadership, business savvy results and commitment to inclusion that our industry needs to thrive in today’s challenging environment.”

“I am incredibly proud to see Jennifer recognized as the HBA 2016 Woman of the Year,” says Daniel O’Day, chief operating officer, Roche. “Jennifer is an exceptional leader with a combination of qualities that make her an invaluable contributor to our industry. Her outstanding business acumen, combined with her highly engaging leadership style and passion for bringing out the best in people, makes her a worthy choice for this award.”

 Jennifer will be honored at the HBA’s 27th annual Woman of the Year (WOTY) event on Thursday, May 12, at the Hilton New York Midtown. The WOTY event, which draws upward of 2,000 women and men from throughout the healthcare industry showcases the HBA’s core purpose of furthering the advancement and impact of women in the business of healthcare. Awards for Honorable MentorSTAR (Strategic Transformation Achievement Recognition) and a group of some 100 Rising Stars and Luminaries, noted for their accomplishments and contributions to the healthcare industry, also will be presented at the WOTY event.

Pharma Guy's insight:

Perhaps one day a "Digitally-Savvy" woman pharma pioneer from my list ( will be chosen WOTY by HBA. 

No comment yet.